Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
, 16 (9), 968-81

EFNS Guideline on the Drug Treatment of Migraine--Revised Report of an EFNS Task Force

Affiliations
Practice Guideline

EFNS Guideline on the Drug Treatment of Migraine--Revised Report of an EFNS Task Force

S Evers et al. Eur J Neurol.

Abstract

Background: Migraine is one of the most frequent disabling neurological conditions with a major impact on the patients' quality of life.

Objectives: To give evidence-based or expert recommendations for the different drug treatment procedures in the particular migraine syndromes based on a literature search and the consensus of an expert panel.

Methods: All available medical reference systems were screened for the range of clinical studies on migraine with and without aura and on migraine-like syndromes. The findings in these studies were evaluated according to the recommendations of the European Federation of Neurological Societies (EFNS) resulting in level A, B, or C recommendations and good practice points.

Recommendations: For the acute treatment of migraine attacks, oral non-steroidal antiinflammatory drug (NSAID) and triptans are recommended. The administration should follow the concept of stratified treatment. Before intake of NSAID and triptans, oral metoclopramide or domperidone is recommended. In very severe attacks, intravenous acetylsalicylic acid or subcutaneous sumatriptan are drugs of first choice. Status migrainosus can be treated by cortoicosteroids, although this is not universally held to be helpful, or dihydroergotamine. For the prophylaxis of migraine, betablockers (propranolol and metoprolol) flunarizine, valproic acid, and topiramate are drugs of first choice. Drugs of second choice for migraine prophylaxis include amitriptyline, naproxen, petasites, and bisoprolol.

Similar articles

  • EFNS Guideline on the Drug Treatment of Migraine - Report of an EFNS Task Force
    Members of the task force: et al. Eur J Neurol 13 (6), 560-72. PMID 16796580.
    Migraine is one of the most frequent disabling neurological conditions with a major impact on the patients' quality of life. To give evidence-based or expert recommendati …
  • [Prophylactic Treatments of Migraine]
    H Massiou. Rev Neurol (Paris) 156 Suppl 4, 4S79-86. PMID 11139754. - Review
    Prophylactic treatment is mainly intended to reduce the frequency of migraine attacks. It is usually proposed to patients who suffer from two or more attacks per month. I …
  • Canadian Headache Society Guideline for Migraine Prophylaxis
    T Pringsheim et al. Can J Neurol Sci 39 (2 Suppl 2), S1-59. PMID 22683887.
    There is good evidence from randomized controlled trials for use of a number of different prophylactic medications in patients with migraine. Medication choice for an ind …
  • New "Triptans" and Other Drugs for Migraine
    Med Lett Drugs Ther 40 (1037), 97-100. PMID 9793036.
  • [Treatment of Migraine]
    J Hoffmann et al. Dtsch Med Wochenschr 132 (41), 2153-8. PMID 17924297. - Review
    Migraine attacks are characterized as unilateral and pulsating headache with autonomic features. In about 15 % of Migraine patients the attacks are accompanied by, mostly …
See all similar articles

Cited by 153 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback